Clinical Intervention Model (CIM)
5-azacitidine use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2015
Anti-PD-1: Descriptive analysis of the use of anti-PD-1 antibodies in cancer patients in Québec’s university teaching hospitals – CIM, descriptive analysis, 2020
Abbreviations and symbols used on prescriptions in Quebec’s University Teaching hospitals – CIM, descriptive analysis, 2016
Antifungal use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2017
Antifungals – Treatment of Yeast Fungemia and Candidemia – Treatment Algorithm (August 2019 version):
- Early treatment of yeast fungemia in adult neutropenic patients
- Early treatment of yeast fungemia in adult NON-neutropenic patients
- Treatment of confirmed candidemia in adults
Biosimilars: State of Knowledge and Recommendations for Quebec’s University Teaching Hospitals – CIM, Comprehensive evaluation, 2017
Bortezomib use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2015
Dexmedetomidine use in intensive care in Quebec’s University Teaching Hospitals based on the utilization criteria established by the TDMP in 2010 – CIM, descriptive analysis, 2010
Evaluation of micafungin (Mycamine™) for the treatment and prevention of Candida infections in pediatric patients – CIM, summary evaluation 2018 – Updated december 2020
The use of Filgrastim in Quebec’s university teaching hospitals (UTHs) – CIM, descriptive analysis, 2018
Descriptive analysis of the pediatric use of filgrastim in Quebec’s university teaching hospitals (UTHs) – CIM, descriptive analysis, 2018
Ipilimumab in the Treatment of Metastatic or Unresectable Advanced Melanoma in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2016
Nivolumab (Opdivo™) – What is the preferred strategy: a weight-based dosage, a fixed dose or a weight-based dosage with a maximum dose? – CIM, summary evaluation 2018
Pembrolizumab (Keytruda™) – What is the preferred strategy: a weight-based dosage, a fixed dose, or a weight-based dosage with a maximum dose? – CIM, summary evaluation 2018
Pertuzumab/trastuzumab in HER-2 positive metastatic breast cancer – CIM, descriptive analysis, 2019
Prescribing and use of Rituximab as Maintenance Therapy for Follicular Lymphoma in Quebec’s University Teaching Hospitals – CIM, summary evaluation 2013
Sugammadex – CIM, descriptive analysis, 2020
Surgical Antibiotic Prophylaxis in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2014
Drug evaluations
Descriptive analysis/drug utilization reviews
Treatment review
Posters
Retrospective Cohort Analysis of Sotrovimab and Remdesivir Use in Ambulatory Patients with COVID-19 in Five Teaching Hospitals in Quebec, Canada presented at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen- April 2023
Descriptive Analysis of first-line non-small cell Lung cancer treatment with Pembrolizumab in tumors expressing PD-L1 ≥ 50% in patients treated in five Québec’s university teaching hospitals (DALP-First study) presented at the Canadian Association of Pharmacy in Oncology (CAPhO) Conference in Toronto – April 2023
Postsurgical Discharge Prescriptions for Opioid-naive Patients in University Teaching Hospitals in Quebec: A Descriptive Analysis presented at the Canadian Society of Hospital Pharmacists conference Together 2023 in Banff – March 2023
Descriptive Analysis of Anti-PD-1 Use in Four Adult University Teaching Hospitals in Québec, Canada. (CAPhO 2020), April 2020, Toronto Online – Video presentation of the poster
Descriptive Analysis of Pertuzumab use in Metastatic Breast Cancer (MCB) in four adult University Teaching Hospital inQuébec, Canada: Data after four years of follow-up. (CAPhO 2020). April 2020, Toronto Online – Video presentation of the poster
Descriptive Analysis of Filgrastim Use in Children in Four University Teaching Hospitals in Québec, Canada (CAPhO 2019), April 2019, Halifax
A clinical intervention model for knowledge transfer: Treatment of candidemia (AMCTS), April 2019, Edmonton
Descriptive Analysis of Filgrastim use in four adult University Teaching Hospital in Quebec(CAPhO 2018), May 2018, Ottawa-Gatineau.
Biosimilars : State of knowledge and recommendation from the Programme de gestion thérapeutique des médicaments – ACMTS, April 2018,Halifax
Descriptive Analysis of antifungals use in five university teaching hospitals in Quebec – ASM Microbe June 2017
5-Azacitidine descriptive analysis – CAPhO 2016, Niagara Falls, April 2016
Bortezomib descriptive analysis – CAPhO 2016, Niagara Falls, April 2016
Descriptive analysis and utilization review of meropenem in five university teaching hospitals – ICAAC, September 2011
Publications/abstracts
Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study) published in Current Oncology – March 2023
Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada. Abstract published in Journal of Clinical Oncology – May 2019
Descriptive analysis of the use of ipilimumab (IPI) in previously treated patients with unresectable stage III or IV metastatic melanoma (MM) in four university hospitals of Quebec, Canada. Abstract published in Journal of Clinical Oncology – May 2016
Descriptive Analysis of Azacitidine Use in Four Adult University Teaching Hospitals in Quebec, Canada. Abstract published in Blood (journal) – December 2015
Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada. Abstract published in Blood (journal) – December 2015
Programme de Gestion Thérapeutique des Médicamen 